Biogena Group Invest AG
Biogena Group Invest AG engages in the provision of dietary supplements. The company is based in Salzburg, Austria.
Biogena Group Invest AG (BIO) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, Biogena Group Invest AG (BIO) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | 41.36% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 127.83 |
Biogena Group Invest AG - Net Assets Trend (2021–2025)
This chart illustrates how Biogena Group Invest AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biogena Group Invest AG (2021–2025)
The table below shows the annual net assets of Biogena Group Invest AG from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-01-31 | €8.70 Million | +2.48% |
| 2024-01-31 | €8.49 Million | -0.32% |
| 2023-01-31 | €8.52 Million | -1.17% |
| 2022-01-31 | €8.62 Million | +295.52% |
| 2021-01-31 | €2.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biogena Group Invest AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 812.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (January 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €828.94K | 9.52% |
| Common Stock | €3.99 Million | 45.85% |
| Other Components | €3.88 Million | 44.63% |
| Total Equity | €8.70 Million | 100.00% |
Biogena Group Invest AG Competitors by Market Cap
The table below lists competitors of Biogena Group Invest AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AlphaTime Acquisition Corp Warrant
NASDAQ:ATMCW
|
$29.26K |
|
ALTAIR RES INC.
F:90AA
|
$29.27K |
|
Randgold Exploration
JSE:RNG
|
$29.29K |
|
RENN Fund Inc
NYSE MKT:RCG
|
$29.35K |
|
TULLETT PREBON
BE:N5C
|
$29.19K |
|
MIBE
PINK:MIBE
|
$29.13K |
|
WOOLWORTHS HLDGS
BE:WN3
|
$29.06K |
|
Whitefield Industrials Ltd
AU:WHF
|
$28.99K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biogena Group Invest AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,492,622 to 8,703,191, a change of 210,569 (2.5%).
- Net income of 330,268 contributed positively to equity growth.
- Other factors decreased equity by 119,699.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €330.27K | +3.79% |
| Other Changes | €-119.70K | -1.38% |
| Total Change | €- | 2.48% |
Book Value vs Market Value Analysis
This analysis compares Biogena Group Invest AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.80x to 1.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-01-31 | €1.09 | €3.06 | x |
| 2022-01-31 | €2.16 | €3.06 | x |
| 2023-01-31 | €2.14 | €3.06 | x |
| 2024-01-31 | €2.13 | €3.06 | x |
| 2025-01-31 | €2.18 | €3.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biogena Group Invest AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 89.73%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.03x
- Recent ROE (3.79%) is below the historical average (4.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 5.35% | 35.42% | 0.14x | 1.05x | €-101.30K |
| 2022 | 8.53% | 222.09% | 0.04x | 1.01x | €-126.80K |
| 2023 | 3.50% | 118.77% | 0.03x | 1.02x | €-553.78K |
| 2024 | 2.03% | 103.82% | 0.02x | 1.04x | €-676.86K |
| 2025 | 3.79% | 89.73% | 0.04x | 1.03x | €-540.05K |
Industry Comparison
This section compares Biogena Group Invest AG's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $641,142,974
- Average return on equity (ROE) among peers: 1.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biogena Group Invest AG (BIO) | €- | 5.35% | N/A | $29.26K |
| AGRANA Beteiligungs-Aktiengesellschaft (AGR) | $1.23 Billion | -0.35% | 1.20x | $137.14 Million |
| Stadlauer Malzfabrik Aktiengesellschaft (STM) | $52.58 Million | 2.57% | 0.00x | $7.40 Million |